Aidea Pharma(SH:688488) Zheng Quan Zhi Xing·2025-08-29 22:42Core Viewpoint - Aidi Pharmaceutical (688488) reported significant growth in its 2025 mid-year financial results, with total revenue reaching 362 million yuan, a year-on-year increase of 100.19%, and a net profit of 9.191 million yuan, up 120.23% from the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 362 million yuan, compared to 181 million yuan in 2024, marking a 100.19% increase [1] - The net profit for the same period was 9.191 million yuan, a turnaround from a loss of 45.4346 million yuan in 2024, reflecting a 120.23% improvement [1] - The gross profit margin increased to 65.58%, up 34.53% year-on-year, while the net profit margin improved to 7.31%, a 129.12% increase [1] - Total expenses (sales, management, and financial) amounted to 175 million yuan, accounting for 48.41% of revenue, down 20.19% from the previous year [1] Cash Flow and Debt - Cash and cash equivalents increased to 378 million yuan, a 74.36% rise from 217 million yuan in 2024 [1] - Accounts receivable decreased by 30.71% to 141 million yuan, indicating improved collection efficiency [1] - Interest-bearing liabilities rose to 528 million yuan, a 32.59% increase from 398 million yuan [1] Earnings Per Share - Earnings per share (EPS) improved to 0.02 yuan, compared to a loss of 0.11 yuan in 2024, representing an increase of 118.18% [1] - Operating cash flow per share was 0.06 yuan, up 131.20% from a negative 0.19 yuan in the previous year [1] Investment Interest - Several funds have newly entered the top ten shareholders of Aidi Pharmaceutical, including Penghua Medical Technology Stock A and Xingquan Global Vision Stock, indicating growing institutional interest [3]